SUCLA2 defects have been associated with mitochondrial DNA (mtDNA) depletion and the triad of hypotonia, dystonia/Leighlike syndrome, and deafness. A 9-year-old Brazilian boy of consanguineous parents presented with psychomotor delay, deafness, myopathy, ataxia, and chorea. Despite the prominent movement disorder, brain magnetic resonance imaging (MRI) was normal while 1 H-magnetic resonance spectroscopy (MRS) showed lactate peaks in the cerebral cortex and lateral ventricles. Decreased biochemical activities of mitochondrial respiratory chain enzymes containing mtDNA-encoded subunits and mtDNA depletion were observed in muscle and fibroblasts. A novel homozygous mutation in SUCLA2, the first one in the ligase coenzyme A (CoA) domain of the protein, was identified. Escalating doses of CoQ 10 up to 2000 mg daily were associated with improvement of muscle weakness and stabilization of the disease course. The findings indicate the importance of screening for mitochondrial dysfunction in patients with complex movement disorders without brain MRI lesions and further investigation for potential secondary CoQ 10 deficiency in patients with SUCLA2 mutations.
Mitochondrial DNA depletion syndrome comprises a group of clinically and genetically heterogeneous disorders with reduction of mitochondrial DNA (mtDNA) copy number in tissues, leading to decreased synthesis of mitochondrial respiratory chain complexes. 1 Mutations in 10 nuclear genes have been identified as causes of mitochondrial DNA depletion syndrome (TK2, DGUOK, POLG, MPV17, RRM2B, SUCLA2, SUCLG1, MGME1, C10orf2, and FBXL4) mainly encoding protein involved directly at the DNA replication fork or in the metabolism of deoxynucleotide triphosphate precursors pools for mtDNA replication. 2, 3 SUCLA2 and SUCLG1 genes encode the b and a subunits of succinyl-coenzyme A (CoA) synthase, which interacts with the mitochondrial nucleoside diphosphate kinase, an enzyme required for the mitochondrial deoxynucleotide salvage pathway. 4 Homozygous mutations in SUCLA2 were first identified in 2 cousins from a consanguineous Israeli-Muslim family with an autosomal recessive mitochondrial encephalomyopathy, severe mtDNA depletion in muscle (32%) and defects in the activities of complex I and IV of the respiratory chain. 5 In addition, 16 patients from the Faroe Islands and 8 Caucasian have been described [6] [7] [8] [9] with the clinical triad hypotonia, dystonia/Leigh-like syndrome, and deafness, and the metabolic profile of methylmalonic aciduria caused by SUCLA2 deficiency.
Here, the authors report a novel mutation in SUCLA2 in a Brazilian child with deafness, myopathy, and a complex movement disorder characterized by chorea and ataxia.
Case Summary
A 9-year-old boy of consanguineous parents with mixed ethnic backgrounds (Portuguese and indigenous Brazilian), presented with early onset chorea, ataxia, and myopathy. He was after an uneventful 36 week pregnancy. There was no family history of neurodegenerative disorders. At age 11 months, he was noted to have delays in motor and language development, which progressed to marked hypotonia, ataxic gait, and frequent falls at age 18 months. After an acute febrile illness at 22 months of age, he became wheelchair-bound. Audiometry revealed 80% hearing loss and, despite the use of hearing aids, he never acquired the ability to talk. He developed chorea and migraine headaches with nausea and vomiting. Signs and symptoms of systemic involvement were also noted with growth retardation, gastrointestinal reflux, as well as incontinence of stool and urine.
At age 4, because of the combination of myopathy and ataxia, he was suspected of having CoQ 10 deficiency and supplementation was started at 300 mg daily. Response to treatment was promptly evident: 2 weeks later, he regained the ability to hold his head up, to sit unassisted, and to crawl with difficulty.
At the latest clinical evaluation at age 9 years, he was taking CoQ 10 2,000 mg daily and L-carnitine 1,200 mg daily, thiamine 100 mg daily, and biotin 10 mg daily. Relative to the examination 3 years prior, choreic and ataxic movements appeared stable while improvement in muscle weakness was evident (Video 1). He was able to walk without support and communicate with sign language. Brain magnetic resonance images (MRIs) were normal at ages 3, 6, and 9 years-old, but brain 1 H-magnetic resonance spectroscopy (MRS) revealed lactate peaks in the cerebral cortex and lateral ventricles ( Metabolic tests showed elevated fasting venous lactate (57.7 mg/dl, nl 4.5-14.4) and cerebrospinal fluid (29 mg/dl, nl 9-16) and normal plasma and urine amino acids; while urine organic acid profiles showed variable increases of lactic acid and 3-hydroxy-isovaleric acid and 3-methylglutaconic acid.
Quadriceps muscle biopsy showed ragged-red fibers, hyperactivity of reduced nicotinamide adenine dinucleotide (NADH), and succinate dehydrogenase, type I fiber predominance, and lipid droplets ( Figure 1F -H). Respiratory chain enzyme activities in muscle showed markedly decreased activities of succinate-cytochrome c reductase (IIþIII) (4% of control mean normalized to citrate synthase, a marker of mitochondrial mass), cytochrome c oxidase (IV) (12%) and NADH-dehydrogenase-cytochrome c reductase (IþIII) (19%). In contrast, the patient's cultured skin fibroblasts showed partial deficits of complexes IIþIII (49%) and IV (75%). Thus, the defects in respiratory chain activities in muscle, but not in fibroblasts fulfill Walker major diagnostic criterion (<20% activity of control mean) for mitochondrial disease. 10 Quantitation of mtDNA by real-time PCR revealed 16% residual mtDNA in muscle and 63% in fibroblasts relative to normal controls (Supplemental Table 1 ).
High-density genome-wide single nucleotide polymorphism (SNP) genotyping by hybridization of total genomic DNA extracted from patient fibroblasts on Human 660w-quad Bead-Chips (Illumina Inc, San Diego, CA) was performed and SNP data were analyzed using BeadStudio v3 (Illumina Inc). Twelve chromosomal loci revealed homozygosity in the patient and genes known or predicted to encode mitochondrial proteins were studied by Sanger sequence.
A novel homozygous variation c.1276C>T (p.Arg407Trp) in SUCLA2 was identified in a high conserved amino acid residue, localized in the ligase CoA domain of the protein.
The missense change was predicted to be ''probably damaging'' by Polyphen (http://genetics.bwh.harvard.edu/pph/), was heterozygous in both parents, and absent in dbSPN137 database and in the DNA from 100 healthy individuals tested by sequencing. 
Discussion
Inborn errors of metabolism comprise a heterogeneous group of disorders often presenting with complex clinical syndromes characterized by psychomotor retardation, pyramidal signs, epilepsy, and movement disorders. Childhood-onset movement disorders such as ataxia and dystonia have been frequently described in mitochondrial disorders and are often due to Leigh or Leigh-like lesions in basal ganglia or cerebellar atrophy.
Here, the authors present describe the first patient with a SUCLA2 defect, presenting with psychomotor retardation, ataxia, chorea, myopathy, and deafness. Despite the complex movement disorder, no brain lesions were identified MRI scans, while abnormal lactic acid peaks were present in both the cerebral cortex and ventricles. Defects in SUCLA2 have been associated with muscle mtDNA depletion and severe progressive mitochondrial encephalomyopathy with psychomotor retardation, feeding problems, hearing loss, speech delay and Leigh-like brain lesions and occasional additional manifestations ( Table 1) . Normal brain MRIs have been described in only 2 patients with early childhood onset and devastating disease courses.
In patients with SUCLA2 defects, metabolic assessments have shown elevations of citric acid intermediates, L-leucine metabolites, lactic acid that are considered important markers for the genetic diagnosis. 8, 11 The metabolic profile in the patient together with those of reported cases 9,12 demonstrated variable abnormalities of intermediate metabolites, but lactic acidosis was more consistently detected in both plasma and brain MRIs. This report underscores the importance of screening for mitochondrial dysfunction using brain magnetic resonance spectroscopy in patients with complex movement disorder without brain MRI lesions.
The authors confirmed the presence of severe mtDNA depletion in muscle of SUCLA2 mutant patients, and also found reduction of mtDNA copy number in fibroblasts, a peculiar finding in dividing cells, that has been described in only 2 out of 24 patients. 13 The pathogenic pathway linking SUCLA2 defects and mtDNA maintenance is still unknown. Loss of interaction between succinyl-CoA synthase and mitochondrial nucleoside diphosphate kinase, followed by secondary deficiency of the mitochondrial deoxyribonucleotide diphosphate phosphorylation have been postulated to impair mtDNA synthesis. 5, 14 Therapeutic strategies in mitochondrial disorders include supportive or disease modifying treatment. Early nutritional support in the first months of life delayed the disease progression in 3 children with SUCLA2 mutations from Faroe Island. In this patient coenzyme Q 10 supplementation appeared to improve muscle weakness and stabilized the clinical course of the disease.
This report contributes to expand the spectrum of SUCLA2 mutations adding a milder phenotype in which ataxia and chorea were the main debilitating and severe symptoms. Although the limited number of patients reported does not allow genotype-phenotype correlation, the mutation in the ligase CoA domain may explain the milder phenotype observed in the authors' patient.
